Hemorrhagic stroke management
Hemorrhagic stroke Microchapters |
Diagnosis |
---|
Treatment |
AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage (2015) |
AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage (2012) |
AHA/ASA Guideline Recommendation for the Primary Prevention of Stroke (2014) |
AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (2014) Sex-Specific Risk Factors
Risk Factors Commoner in Women |
Case Studies |
Hemorrhagic stroke management On the Web |
American Roentgen Ray Society Images of Hemorrhagic stroke management |
Risk calculators and risk factors for Hemorrhagic stroke management |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical therapy
Anticoagulants and antithrombotics, key in treating ischemic stroke, can make bleeding worse and cannot be used in intracerebral hemorrhage. Patients are monitored and their blood pressure, blood sugar, and oxygenation are kept at optimum levels.
Coagulation factor deficiency or platelet disorder treatments
For patients with a known coagulation factor deficiency or platelet disorder,
- Replacement of the appropriate factor or platelets
- Hematology consult
patient undergoing an IV heparin infusion
- Protamine sulfate IV injection at a dose of 1 mg per 100 U of heparin (maximum dose 50 mg) with adjustment based on time elapsed since discontinuation of heparin infusion
Patients who are receiving low-molecular-weight heparin (reversal may be incomplete)
- Protamine sulfate IV injection at a dose of 1 mg per 100 U of heparin (maximum dose 50 mg)
Vitamin K antagonists (VKAs)
Rapid correction of the international normalized ratio (INR) is recommended.
- Fresh frozen plasma (FFP), along with vitamin K (5 to 10 mg, usually given slowly via the IV route) has been the mainstay of treatment
Recently new treatments have emerged as potential therapies such as:
- Prothrombin complex concentrates (PCCs) contains factors II, IX, X, and VII. PCC does not require cross matching, can be reconstituted and administered rapidly in a small volume (20–40 mL)
- Activated PCC FEIBA (factor VIII inhibitor bypassing activity)
- Recombinant activated factor VIIa (rFVIIa)